Anika Therapeutics, Inc.
ANIKUS売上高
$113M
百万USD
営業利益
$-11M
百万USD
純利益
$-11M
百万USD
ROE
-7.6%
最新FY
EPS
$-0.76
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $34M | $3M | $0.20 |
| FY2021 | Q2 | $38M | $7M | $0.45 |
| FY2021 | Q3 | $40M | $1M | $0.04 |
| FY2021 | FY | $148M | $4M | $0.28 |
| FY2022 | Q1 | $37M | $-3M | $-0.20 |
| FY2022 | Q2 | $40M | $-3M | $-0.20 |
| FY2022 | Q3 | $40M | $-4M | $-0.29 |
| FY2022 | FY | $156M | $-15M | $-1.02 |
| FY2023 | Q1 | $38M | $-10M | $-0.71 |
| FY2023 | Q2 | $44M | $-3M | $-0.19 |
| FY2023 | Q3 | $41M | $-7M | $-0.45 |
| FY2023 | FY | $167M | $-83M | $-5.64 |
| FY2024 | Q1 | $41M | $-5M | $-0.31 |
| FY2024 | Q2 | $42M | $-0M | $-0.01 |
| FY2024 | Q3 | $39M | $-30M | $-2.03 |
| FY2024 | FY | $120M | $-56M | $-3.83 |
| FY2025 | Q1 | $26M | $-5M | $-0.34 |
| FY2025 | Q2 | $28M | $-4M | $-0.28 |
| FY2025 | Q3 | $28M | $-2M | $-0.16 |
| FY2025 | FY | $113M | $-11M | $-0.76 |
| FY2026 | Q1 | $30M | $-5M | $-0.37 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $106M | $115M | $130M | $148M | $156M | $167M | $120M | $113M |
| 営業利益 | $51M | $46M | $22M | $34M | $-28M | $3M | $-19M | $-88M | $-5M | $-11M |
| 純利益 | $33M | $32M | $19M | $27M | $-24M | $4M | $-15M | $-83M | $-56M | $-11M |
| 総資産 | $240M | $283M | $279M | $331M | $366M | $348M | $349M | $271M | $203M | $190M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $223M | $263M | $264M | $288M | $272M | $287M | $286M | $212M | $154M | $143M |
| 営業CF | $24M | $41M | $35M | $37M | $13M | $8M | $4M | $-2M | $5M | $11M |
| EPS | $2.15 | $2.11 | $1.27 | $1.89 | $-1.69 | $0.28 | $-1.02 | $-5.64 | $-3.83 | $-0.76 |
| BPS | $15.22 | $17.93 | $18.55 | $20.35 | $18.96 | $19.84 | $19.52 | $14.31 | $10.86 | $10.71 |
| ROE | 14.6% | 12.1% | 7.1% | 9.4% | -8.8% | 1.4% | -5.2% | -38.9% | -36.6% | -7.6% |